(0.12%) 5 528.25 points
(0.17%) 39 538 points
(0.04%) 19 935 points
(0.36%) $81.83
(-1.27%) $2.57
(-0.02%) $2 339.10
(-0.24%) $29.49
(-1.82%) $995.60
(-0.34%) $0.930
(-0.41%) $10.63
(-0.20%) $0.789
(2.07%) $87.50
0.00% $ 5.00
Live Chart Being Loaded With Signals
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments...
Stats | |
---|---|
Tagesvolumen | 2 387 |
Durchschnittsvolumen | 523 |
Marktkapitalisierung | 1.35B |
EPS | $27.45 ( Q4 | 2024-03-31 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-08-08 |
Last Dividend | $0.105 ( 2022-09-29 ) |
Next Dividend | $0 ( N/A ) |
P/E |
8.33 (Sector) 0 (Industry) 0 |
ATR14 | $0 (0.00%) |
Nippon Shinyaku Co., Ltd. Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Nippon Shinyaku Co., Ltd. Finanzdaten
Annual | 2024 |
Umsatz: | $148.26B |
Bruttogewinn: | $97.02B (65.44 %) |
EPS: | $383.82 |
FY | 2024 |
Umsatz: | $148.26B |
Bruttogewinn: | $97.02B (65.44 %) |
EPS: | $383.82 |
FY | 2023 |
Umsatz: | $144.18B |
Bruttogewinn: | $88.20B (61.17 %) |
EPS: | $338.70 |
FY | 2022 |
Umsatz: | $137.48B |
Bruttogewinn: | $87.29B (63.49 %) |
EPS: | $370.97 |
Financial Reports:
No articles found.
Nippon Shinyaku Co., Ltd. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.105 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0575 | 2017-10-02 |
Last Dividend | $0.105 | 2022-09-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 11 | -- |
Total Paid Out | $1.029 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.09 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.47 | |
Div. Directional Score | 9.92 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
29 Sep 2022 | $0.105 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
29 Mar 2022 | $0.108 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
28 Sep 2021 | $0.112 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
29 Mar 2021 | $0.113 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
28 Sep 2020 | $0.118 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
27 Mar 2020 | $0.0997 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
27 Sep 2019 | $0.0986 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
28 Mar 2019 | $0.0950 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
27 Sep 2018 | $0.0640 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
28 Mar 2018 | $0.0586 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
02 Oct 2017 | $0.0575 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
JTEKF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
WDFN | Ex Dividend Junior | 2023-08-10 | Quarterly | 0 | 0.00% | |
FIZN | Ex Dividend Junior | 2023-08-14 | Quarterly | 0 | 0.00% | |
SATLF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
CNBZ | Ex Dividend Junior | 2023-07-26 | Semi-Annually | 0 | 0.00% | |
MCRAB | Ex Dividend Knight | 2023-09-20 | Quarterly | 0 | 0.00% | |
AMNF | Ex Dividend King | 2023-07-06 | Quarterly | 0 | 0.00% | |
HLAN | Ex Dividend Knight | 2023-09-22 | Quarterly | 0 | 0.00% | |
THUPY | Ex Dividend Knight | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
DNKEY | Ex Dividend Junior | 2023-07-28 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.51 | 9.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.0981 | 1.200 | 6.73 | 8.07 | [0 - 0.3] |
returnOnEquityTTM | 0.122 | 1.500 | 9.76 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.310 | -1.000 | 6.90 | -6.90 | [0 - 1] |
currentRatioTTM | 4.40 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.11 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.206 | 1.500 | 4.41 | 6.62 | [0.2 - 2] |
debtRatioTTM | 0.0109 | -1.500 | 9.82 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 102.86 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 241.85 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 98.59 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0130 | -1.500 | 9.95 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.661 | 1.000 | 2.31 | 2.31 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.228 | 1.000 | 7.45 | 7.45 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 5.67 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.563 | 0.800 | 9.58 | 7.66 | [0.5 - 2] |
Total Score | 13.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 2.10 | 1.000 | 9.89 | 0 | [1 - 100] |
returnOnEquityTTM | 0.122 | 2.50 | 9.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 98.59 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0000875 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 241.85 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.310 | 1.500 | 6.90 | -6.90 | [0 - 1] |
pegRatioTTM | 0.00208 | 1.500 | -3.32 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.75 | 0 | [0.1 - 0.5] |
Total Score | 6.47 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.